Dimerix Ltd (DXB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dimerix Ltd (DXB) has a cash flow conversion efficiency ratio of 3.087x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$41.30 Million ≈ $29.22 Million USD) by net assets (AU$13.38 Million ≈ $9.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dimerix Ltd (DXB) net asset quality to measure how much of total assets are equity-financed.
Dimerix Ltd - Cash Flow Conversion Efficiency Trend (1992–2025)
This chart illustrates how Dimerix Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Dimerix Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Dimerix Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dimerix Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quoc Cuong Gia Lai JSC
VN:QCG
|
0.004x |
|
SHANGHAI FUDAN H YC-,10
F:FDY
|
N/A |
|
Kluang Rubber Company Malaya
KLSE:2453
|
-0.001x |
|
DongKook Pharmaceutical Co. Ltd
KQ:086450
|
0.029x |
|
OBI Pharma
TWO:4174
|
-0.176x |
|
Anderson Industrial Corp
TW:1528
|
0.021x |
|
Whanin Pharm
KO:016580
|
0.006x |
|
Sunflow Sustain
TA:SNFL
|
0.059x |
Annual Cash Flow Conversion Efficiency for Dimerix Ltd (1992–2025)
The table below shows the annual cash flow conversion efficiency of Dimerix Ltd from 1992 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Dimerix Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$13.38 Million ≈ $9.47 Million |
AU$39.05 Million ≈ $27.63 Million |
2.919x | +857.87% |
| 2024-06-30 | AU$18.19 Million ≈ $12.87 Million |
AU$-7.00 Million ≈ $-4.96 Million |
-0.385x | +81.96% |
| 2023-06-30 | AU$5.96 Million ≈ $4.22 Million |
AU$-12.73 Million ≈ $-9.01 Million |
-2.135x | -129.17% |
| 2022-06-30 | AU$14.42 Million ≈ $10.20 Million |
AU$-13.44 Million ≈ $-9.51 Million |
-0.932x | +78.83% |
| 2021-06-30 | AU$1.47 Million ≈ $1.04 Million |
AU$-6.46 Million ≈ $-4.57 Million |
-4.401x | -623.25% |
| 2020-06-30 | AU$7.76 Million ≈ $5.49 Million |
AU$-4.72 Million ≈ $-3.34 Million |
-0.608x | +7.03% |
| 2019-06-30 | AU$4.20 Million ≈ $2.97 Million |
AU$-2.75 Million ≈ $-1.95 Million |
-0.655x | -39.16% |
| 2018-06-30 | AU$6.86 Million ≈ $4.85 Million |
AU$-3.23 Million ≈ $-2.28 Million |
-0.470x | +33.66% |
| 2017-06-30 | AU$2.63 Million ≈ $1.86 Million |
AU$-1.86 Million ≈ $-1.32 Million |
-0.709x | -15.29% |
| 2016-06-30 | AU$2.24 Million ≈ $1.59 Million |
AU$-1.38 Million ≈ $-975.82K |
-0.615x | -205.76% |
| 2015-06-30 | AU$2.78 Million ≈ $1.96 Million |
AU$-558.55K ≈ $-395.21K |
-0.201x | +58.31% |
| 2014-06-30 | AU$1.18 Million ≈ $834.33K |
AU$-568.88K ≈ $-402.52K |
-0.482x | +97.30% |
| 2014-04-30 | AU$31.22K ≈ $22.09K |
AU$-558.55K ≈ $-395.21K |
-17.893x | -9885.60% |
| 2013-06-30 | AU$1.71 Million ≈ $1.21 Million |
AU$-305.90K ≈ $-216.44K |
-0.179x | +9.01% |
| 2012-06-30 | AU$1.18 Million ≈ $834.76K |
AU$-232.33K ≈ $-164.39K |
-0.197x | +5.57% |
| 2011-06-30 | AU$1.57 Million ≈ $1.11 Million |
AU$-326.54K ≈ $-231.04K |
-0.209x | +12.93% |
| 2010-06-30 | AU$1.56 Million ≈ $1.10 Million |
AU$-373.67K ≈ $-264.39K |
-0.240x | +95.32% |
| 2009-06-30 | AU$341.98K ≈ $241.97K |
AU$-1.75 Million ≈ $-1.24 Million |
-5.113x | -114.66% |
| 2008-06-30 | AU$1.01 Million ≈ $713.34K |
AU$-2.40 Million ≈ $-1.70 Million |
-2.382x | -103.42% |
| 2007-06-30 | AU$1.41 Million ≈ $1.00 Million |
AU$-1.66 Million ≈ $-1.17 Million |
-1.171x | -56.68% |
| 2006-06-30 | AU$2.69 Million ≈ $1.91 Million |
AU$-2.01 Million ≈ $-1.42 Million |
-0.747x | -405.76% |
| 2005-06-30 | AU$10.28 Million ≈ $7.27 Million |
AU$-1.52 Million ≈ $-1.07 Million |
-0.148x | -102.79% |
| 2004-06-30 | AU$-170.38K ≈ $-120.55K |
AU$-902.37K ≈ $-638.48K |
5.296x | +422.93% |
| 2003-06-30 | AU$-565.02K ≈ $-399.79K |
AU$-572.26K ≈ $-404.91K |
1.013x | +147.45% |
| 2002-06-30 | AU$282.89K ≈ $200.16K |
AU$-603.82K ≈ $-427.24K |
-2.135x | -1434.07% |
| 2001-06-30 | AU$640.43K ≈ $453.14K |
AU$102.47K ≈ $72.50K |
0.160x | +74.25% |
| 2000-06-30 | AU$5.24 Million ≈ $3.71 Million |
AU$481.16K ≈ $340.45K |
0.092x | -48.60% |
| 1999-06-30 | AU$5.77 Million ≈ $4.08 Million |
AU$1.03 Million ≈ $729.49K |
0.179x | +303.76% |
| 1997-06-30 | AU$1.96 Million ≈ $1.39 Million |
AU$-171.60K ≈ $-121.42K |
-0.088x | -29.69% |
| 1996-06-30 | AU$1.85 Million ≈ $1.31 Million |
AU$-125.03K ≈ $-88.47K |
-0.068x | +5.26% |
| 1995-06-30 | AU$1.72 Million ≈ $1.22 Million |
AU$-123.00K ≈ $-87.03K |
-0.071x | -16.09% |
| 1994-06-30 | AU$1.74 Million ≈ $1.23 Million |
AU$-107.00K ≈ $-75.71K |
-0.061x | -147.59% |
| 1993-06-30 | AU$1.41 Million ≈ $997.66K |
AU$-35.00K ≈ $-24.76K |
-0.025x | -299.35% |
| 1992-06-30 | AU$1.04 Million ≈ $738.70K |
AU$13.00K ≈ $9.20K |
0.012x | -- |
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more